Saphnelo Side Effects

Generic name: anifrolumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Nov 15, 2023.

Note: This document provides detailed information about Saphnelo Side Effects associated with anifrolumab. Some dosage forms listed on this page may not apply specifically to the brand name Saphnelo.

Applies to anifrolumab: intravenous solution.

Serious side effects of Saphnelo

Along with its needed effects, anifrolumab (the active ingredient contained in Saphnelo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking anifrolumab:

Other side effects of Saphnelo

Some side effects of anifrolumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to anifrolumab: intravenous solution.

General adverse events

The most common adverse drug reactions with an incidence of 5% or greater were nasopharyngitis, upper respiratory tract infections, urinary tract infection, bronchitis, infusion related reactions, herpes zoster, headache, back pain, sinusitis, and cough.^[Ref]

Gastrointestinal

• Common (1% to 10%): Diarrhea, nausea, oral herpes, vomiting

Genitourinary

• Very common (10% or more): Urinary tract infection (12%)

Hypersensitivity

• Common (1% to 10%): Hypersensitivity
• Uncommon (0.1% to 1%): Anaphylactic reaction^[Ref]

Serious hypersensitivity reactions were reported in 0.6% of patients.^[Ref]

Immunologic

• Common (1% to 10%): Antibody development^[Ref]

Local

• Common (1% to 10%): Infusion-related reactions^[Ref]

The most common infusion-related reaction symptoms were headache, nausea, vomiting, fatigue, and dizziness.^[Ref]

Musculoskeletal

• Common (1% to 10%): Back pain, arthralgia

Nervous system

• Common (1% to 10%): Headache

Oncologic

• Uncommon (0.1% to 1%): Malignancies^[Ref]

Malignant neoplasms, included non-melanoma skin cancers, were reported in 1.3% of patients.

Malignancies that were reported in more than one patient included breast cancer and squamous cell carcinoma.^[Ref]

Other

• Very common (10% or more): Infections (69.7%)
• Common (1% to 10%): Herpes zoster, serious Infections^[Ref]

The most frequent serious infection was pneumonia.

Fatal infections occurred in 0.4% of patients.^[Ref]

Respiratory

• Very common (10% or more): Bronchitis (11%), upper respiratory tract infection (34%), nasopharyngitis (16.3)
• Common (1% to 10%): Cough, respiratory tract infection, sinusitis, cough, pharyngitis, pneumonia^[Ref]

Upper respiratory tract infections included nasopharyngitis and pharyngitis.

Bronchitis included viral bronchitis and tracheobronchitis.

Respiratory tract infection included viral respiratory tract infection and bacterial respiratory tract infection.^[Ref]

Frequently asked questions

• What is the difference between Benlysta and Saphnelo?

Further information

Saphnelo side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer